The biotec sector in India is experiencing significant growth, driven by advancements in research, innovation, and government support. India is emerging as a global hub for biotechnology, with opportunities in areas like pharmaceuticals, healthcare, agriculture, and industrial biotechnology.
The sector benefits from a skilled workforce, increasing investments, and a growing focus on biopharmaceuticals and gene editing. Companies like Biocon, Serum Institute of India, and Dr. Reddy’s Laboratories are key players in the industry.
The expanding demand for vaccines, biosimilars, and agricultural biotec solutions presents enormous growth potential, positioning India as a leader in the global biotec landscape.
Share Price
The shares of Onyx Biotec are currently trading at Rs. 83.8 up by 1.02% from its previous close of Rs. 81.65. The stock is going through a volatile trading session as the stock collapsed 8% in the morning hours hitting a low of Rs. 75 and jumping back to green during the intraday trade.
Recent Updates
In a recent development, Shoora Resource Private Limited, a Domestic Institutional Investor (DII), acquired 1 lakh shares of Onyx Biotec at Rs 73.97 per share. Similarly, Acintyo Investment Fund PCC, a Foreign Institutional Investor (FII), purchased 1.44 lakh shares of the company at Rs 77.05 per share.
These investments indicate growing institutional interest in Onyx Biotec, reflecting confidence in the company’s prospects. Such transactions can potentially boost the company’s stock value and attract further investor attention. The involvement of both domestic and foreign investors highlights the appeal of Onyx Biotec in the market.
About the Company
Incorporated in 2005, Onyx Biotec Ltd (OBL) is a leading manufacturer and supplier of sterile pharmaceutical products, including Sterile Water for Injections, Dry Powder Injections, and Dry Syrup. Operating through a B2B business model, OBL serves both domestic and international markets.
The company is a prominent player in the healthcare sector, supplying major corporations with high-quality sterile products. OBL offers end-to-end product development and manufacturing solutions, including the preparation and filing of regulatory dossiers in India and global markets.
With a strong focus on quality, the company is well-positioned in the pharmaceutical contract manufacturing space.
Written By: Dipangshu Kundu
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
